CATECHOL O-METHYLTRANSFERASE ENZYME COFACTOR S-ADENOSYL L METHIONINE AND RELATED MECHANISMS

被引：0

作者：

Muller, Thomas ^{[1
]}

机构：

[1] St Joseph Hosp, Dept Neurol, Berlin, Germany

来源：

BASIC ASPECTS OF CATECHOL-O-METHYLTRANSTERASE AND THE CLINICAL APPLICATIONS OF ITS INHIBITORS | 2010年 / 95卷

关键词：

PLASMA HOMOCYSTEINE LEVELS; LEVODOPA-TREATED PATIENTS; MTHFR C677T GENOTYPE; PARKINSONS-DISEASE PATIENTS; L-DOPA; CEREBROSPINAL-FLUID; N-METHYLTRANSFERASE; IRON-METABOLISM; COMT INHIBITOR; FOLIC-ACID;

D O I：

10.1016/B978-0-12-381326-8-00004-1

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Long term daily repeated intake of traditional levodopa (L dopa)/dopa decarboxylase inhibitor (DDI) formulations increases the homocysteine synthesis in plasma of Parkinson s disease patients with unforeseen consequences like an augmented vulnerability for onset of concomitant non motor symptoms Homocysteine decrease may therefore be a future therapeutic challenge which may be achieved by supplementation with certain vitamins or by combination of a catechol O methyltransferase (COMT) inhibitor with L dopa/DDI administration Monitoring of plasma homocysteine concentration may also serve as biomarker for the detoxification potential of endogenous, exogenous and environmental toxins These substrates may also accumulate in the nervous system since homocysteine formation is associated with O methylation which has a broad detoxification potential

引用

页码：49 / 71

页数：23